Workshop: Methamphetamine-Associated Psychosis (MAP): Clinical Challenges and Approaches to Management

Abstract

This workshop will review recent trends associated with methamphetamine in the United States. Specifically, changes in prevalence of methamphetamine use will be discussed, as well as observed changes in the methamphetamine product itself (e.g. potency, purity, price) which may have an impact on psychosis. Background on the clinical characteristics of methamphetamine-associated psychosis (MAP) will be explored, as well as its association with schizophrenia, and its hypothesized pathophysiology. Clinical strategies to differentiate MAP from schizophrenia will also be provided. Treatment approaches to MAP will be described, ranging from a general review of evidence-based treatments for MUD, to specific treatments for the psychotic symptoms within MAP. Finally, panel members will share perspectives on the clinical approach to MAP informed by experience and a mix of published and unpublished data.

Learning Objectives

Discuss the methamphetamine epidemic, focusing on the changing characteristics and pharmacology of methamphetamine, its production, and its use, on a national scale (Meth 2.0)
Describe the background of methamphetamine-associated psychosis, including its possible pathophysiology and relationship to schizophrenia
Discuss treatment strategies that specifically target psychosis among individuals who use methamphetamine

Keywords / Topics

Methamphetamine
Psychosis
Clinical Treatment

Presenters

Michael Zito, MD, Chairperson

Dr. Zito holds a faculty position at the UCLA Semel Institute, where he also completed residency training. After residency, he completed a research fellowship at the VA Greater Los Angeles. His academic and research interests involve individuals with psychosis who use methamphetamine.

Larissa Mooney, MD, Presenter

Larissa Mooney, M.D. is a Professor of Clinical Psychiatry and Director of the Addiction Psychiatry Division in the Department of Psychiatry and Biobehavioral Sciences at UCLA. She is the Director of the UCLA-VA Addiction Psychiatry Fellowship Program and previously served as the Section Chief for Substance Use Disorders at the Greater Los Angeles VA. Dr. Mooney is the President of the American Academy of Addiction Psychiatry (AAAP) and a Distinguished Fellow of the American Psychiatric Association (APA). She is one of two Principal Investigators for the Greater Southern California Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network.

Jose Flores, MD, PhD, MPH, Presenter

Dr. José Flores is a Child and Adolescent Psychiatry fellow at the University of California, Los Angeles (UCLA), and is interested in interventions for youth with psychiatric and substance use disorders. Dr. Flores completed medical school and obtained his PhD in epidemiology from Johns Hopkins University. He subsequently went on to complete psychiatry residency and addiction psychiatry fellowship at Yale University. At Yale, Dr. Flores was a T32 post-doctoral fellow in pediatric neuropsychiatric disorders at the Yale Child Study Center and worked with US. Veterans at the Veteran Affairs Hospital in West Haven, Connecticut. At the VA, Dr. Flores worked in multiple addiction clinics including the hospital’s methadone program.

Summary


Availability:	On-Demand


Cost:	FREE


Credit Offered:	No Credit Offered

Create Account

	The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.		400 Massasoit Avenue Suite 307 East Providence, RI 02914 cmecpd@aaap.org	About Advocacy Membership Fellowship Education and Resources Training Events